TherapeuticsMD Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
TherapeuticsMD (TXMD) PT Lowered to $5 at Stifel
May 6, 2021 2:00 PM EDTStifel analyst Annabel Samimy lowered the price target on TherapeuticsMD (NASDAQ: TXMD) to $5.00 (from $6.00) while maintaining a Buy rating.
The analyst commented, "While investor worry remained at a peak, TXMD posted sales of $19.9mn/Cons $19,8mn, with FDA-product sales of $18.3mn coming... More
TherapeuticsMD (TXMD) Tops Q1 EPS by 1c, Revenues Beat
May 6, 2021 7:11 AM EDTTherapeuticsMD (NASDAQ: TXMD) reported Q1 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $19.9 million versus the consensus estimate of $19.77 million.
I am pleased with our ongoing execution across the organization, which is in-line with our 2021... More
